Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TriLink BioTechnologies, Inc. Announces License Agreement with LI-COR Biosciences

Published: Friday, October 19, 2012
Last Updated: Friday, October 19, 2012
Bookmark and Share
TriLink BioTechnologies Inc. (TriLink) announced that it has recently signed a licensing agreement with LI-COR® Biosciences to custom label oligonucleotides, nucleotides, and nucleosides with IRDye® near-infrared dyes.

"This offers our customers a product option that will be more specific to their research, while being based on the IRDye near-infrared dye technology they have grown to trust," says Jim Wiley, LI-COR senior strategic marketing manager. "TriLink has established itself as an expert in the field of modified nucleic acids and we're certain our customers will benefit from this agreement."

LI-COR offers IRDye near-infrared dye technology that delivers enhanced sensitivity due to low background autofluorescence in the near-infrared region and, therefore, higher signal to noise ratios. IRDye near-infrared dyes have absorption and emission wavelengths in the near-infrared spectrum, between 650 nm and 800 nm.

"As experts in modified nucleic acid chemistry and leaders in dye labeling nucleoside triphosphates and oligonucleotides, we are continually expanding our portfolio of available modifications," says Richard Hogrefe, Ph.D., TriLink president and CEO. "The innovative LI-COR infrared dye series, IRDye 650-800, is a perfect fit, opening new doors for our customers seeking enhanced signal-to-noise ratios and dynamic range in applications where autofluorescence is an issue."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TriLink BioTechnologies Announces Agreement with American Cleanroom Systems to build cGMP Facility
Agreement signed to build a 2,000 square foot pharmaceutical cGMP production suite within San Diego facility.
Thursday, October 24, 2013
TriLink Enters into Distribution Agreement with Astral Scientific
The agreement allows Astral to sell Trilink's modified nucleic acid products, including over 150 modified nucleotides, custom oligonucleotides and CleanAmp™ Hot Start PCR Products. The Australian based company supplies clinical diagnostic, life science and industrial markets.
Tuesday, November 15, 2011
TriLink Awarded Phase I Grant for a Second Hot Start PCR Project
TriLink Biotechnologies has received a $100,000 Phase I SBIR grant from the National Institutes of Health, to study an approach to PCR activation.
Tuesday, May 22, 2007
TriLink Awarded Phase II Grant for Start PCR Project
TriLink will optimize protocols for scale up and automated synthesis, in preparation for commercialization of the technology in early 2007.
Thursday, July 27, 2006
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!